Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: Results of a phase I/II clinical trial

Journal of Gastroenterology

Volumn 38, Issue SUPPL. 15, 2003, Pages 78-84

  Salmons, Brian ^a   Löhr, Matthias ^b   Günzburg, Walter H ^c  

^a Austrianova   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Cell therapy; Cytochrome P450; Encapsulated cells; Genetically modified cells; Pancreatic cancer

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 6 THIOXANTHINE; ACICLOVIR; CELLULOSE SULFATE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME; CYTOCHROME P450 2B1; CYTOSINE DEAMINASE; DRUG METABOLITE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GEMCITABINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IFOSFAMIDE; LIVER ENZYME; MESNA; NITROREDUCTASE; PROTECTIVE AGENT; PURINE DERIVATIVE; SODIUM CHLORIDE; THYMIDINE KINASE; THYMINE ARABINOSIDE;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC REACTION; ALLOGRAFT; ANGIOGRAPHY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL ENCAPSULATION; CELL PROTECTION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MODIFICATION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG USE; ENZYME SPECIFICITY; GENE OVEREXPRESSION; GRAFT REJECTION; GROWTH INHIBITION; HUMAN; IMPLANTATION; INOPERABLE CANCER; LOW DRUG DOSE; NONVIRAL GENE DELIVERY SYSTEM; PAIN ASSESSMENT; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; SYSTEMIC DISEASE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; WEIGHT REDUCTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL TRANSPLANTATION; CYTOCHROME P-450 CYP2B1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; HUMANS; IFOSFAMIDE; INFUSIONS, INTRALESIONAL; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0037255792     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer. Frontiers in Bioscience 1998;3:214-25.
2. Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
3. Halloran CM, Ghaneh P, Neoptolemos JP, Costello E. Gene therapy for pancreatic cancer: current and prospective strategies. Surg Oncol 2000;9:181-91.
4. Gunzburg WH, Salmons B. Novel clinical strategies for the treatment of pancreatic cancer. Trends Mol Med 2001;7:30-7.
5. Uckert W, Kammertöns T, Haack K, Qin Z, Gebert J, Schendel DJ, et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 1998;9:855-65.
6. Kammertöns T, Gelbmann W, Karle P, Saller R, Salmons B, Günzburg WH, et al. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther 2000;7:629-36.
7. Carrio M, Visa J, Cascante A, Estivill X, Fillat C. Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSV-tk/GCV system. J Gene Med 2002;4:141-9.
8. Takahasi K. Models of selective mating and the initiation of the Fisherian process. Proc R Soc Lond B Biol Sci 1997;264:839-44.
9. Block A, Chen SH, Kosai K, Finegold M, Woo SL. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 1997;15:25-34.
10. Shiau A-L, Yang H-M, Wu P, Wu C-L. Provision of postive and negative selections in retroviral vectors containing the cytosine deaminase gene. Gene Ther 1998;5:1571-4.
11. Carrio M, Romagosa A, Mercade E, Mazo A, Nadal M, Gomez-Foix A-M, et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 1999;6: 547-53.
12. Howard BD, Boenicke L, Scniewind B, Henne-Bruns D, Kalthoff H. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex viorus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir. Cancer Gene Ther 2000;7:927-38.
13. Makinen K, Loimas S, Wahlfors J, Alhava E, Janne J. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J Gene Med 2000;2:361-7.
14. Haack K, Linnebacher M, Eisold S, Zoller M, von Knebel Doeberitz M, Gebert J. Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther 2000;7:1357-64.
15. Kanyama H, Tomita N, Yamano T, Aihara T, Miyoshi Y, Ohue M, et al. Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res 2001;61:14-8.
16. Zheng X, Johansson M, Karlsson A. Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem 2000; 275:39125-9.
17. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993;33:36-42.
18. Cerny T, Martinelli G, Goldhirsch A, Terrier F, Joss R, Fey MF, et al. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 1991;117:S135-8.
19. Keizer HJ, Ouwerkerk J, Welvaart K, van der Velde CJH, Cleton FJ. Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 1995;121:297-302.
20. Löhr M, Saller RM, Salmons B, Gunzburg WH. Microencapsulation of genetically engineered cells for cancer therapy. Methods Enzymol 2002;346:603-18.
21. Löhr M, Müller P, Karle P, Stange J, Mitzner S, Jesnowski R, et al. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther 1998;5:1070-8.
22. Kröger JC, Bergmeister H, Hoffmeyer A, Ceijna M, Karle P, Saller R, et al. Intra-arterial instillation of microencapsulated cells in the pancreatic arteries in pig. Ann NY Acad Sci 1999;880:374-8.
23. Löhr JM, Bago ZT, Bergmeister H, Ceijka M, Freund M, Gelbmann W, et al. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced stage pancreatic carcinoma: a phase I/II study. J Mol Med 1999;77:393-8.
24. Gunzburg WH, Karle P, Renz R, Salmons B, Renner M. Characterisation of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy. Ann NY Acad Sci 1999;880:326-36.
25. Shaw G, Morse S, Aarat M, Graham FL. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 2002;16:869-71.
26. Dautzenberg H, Schuldt U, Grasnick G, Karle P, Müller P, Löhr M, et al. Development of cellulose sulphate based polyelectrolyte complex microcapsules for medical applications. Ann NY Acad Sci 1999;875:46-63.
27. Lindemann A, Rosenthal FM, Hase S, Markmeyer P, Mertelsmann R. Guidelines for the design and implementation of clinical studies in somatic cell therapy and gene therapy. J Mol Med 1995;73:207-11.
28. ICH. Topic E6 guideline for good clinical practice: step 5, consolidated guideline. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit EMEA/ NIH; 1996.
29. Hermanek P, Hutter R, Sobin L, Wagner G, Wittekind C. TNM atlas, illustrated guide to the TNM/pTNM classification of malignant tumors. New York: Springer, 1997.
30. Program CTE. Common toxicity criteria, version 2.0. Washington, DC: DCTD, NCI, NIH, DHHS, 1998.
31. WHO. Handbook for reporting results of cancer treatment. Geneva: WHO, 1979.
32. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr, Crowley J. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989;81:485-95.
33. Bloechle C, Izbicki JR, Knoefel WT, Kuechler T, Broelsch CE. Quality of life in chronic pancreatitis: results after duodenum-preserving resection of the head of the pancreas. Pancreas 1995;11:77-85.
34. Löhr JM, Hoffmeier A, Kröger J-C, Freund M, Hain J, Holle A, et al. Microencapsulated cell mediated therapy of inoperable pancreatic carcinoma; a phase I/II study. Lancet 2002;357:1591-2.
35. Karle P, Renner M, Salmons B, Günzburg W. Necrotic, rather than apoptotic, cell death caused by cytochrome P450 activated ifosfamide. Cancer Gene Ther 2001;8:200-30.
36. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 2001;60: 1268-79.
37. Löhr JM, Kröger JC, Hoffmeyer A, Benz S, Müller P, Saller R, et al. Intra-arterial instillation of microencapsulated, ifosfamide activating cells in the pig pancreas for chemotherapeutic targeting. Pancreatology 2003;3:in press.
38. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-5.
39. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer (Phila) 1999;85:1261-8.
40. Rieger J, Durka S, Streffer J, Dichgans J, Weller M. Gemcitabine cytotoxicity of human malignant glioma cells and modulation by antioxidants, Bcl-2 and dexamethasone. Eur J Pharmacol 1999; 365:301-8.
41. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
42. Loehrer PJ, Williams SD, Einhorn LH, Ansari R. Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 1985;3:367-72.
43. Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, et al. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 1988;6:1703-7.
44. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TKH, Kowall NW, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994;5:969-78.
45. Chen L, Waxmann D. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of combined chemotherapy/ cancer gene therapy strategy. Cancer Res 1995;55:581-9.
46. Dondelinger R. Advances in abdominal interventional radiology. Lancet 1999;353:SI15-8.
47. Trinchet JC. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
48. Talamonti M, Tellez C, Benson A. Local-regional therapy for metastatic liver tumors. Cancer Treat Res 1998;98:172-99.